NCT03920579

A Clinical Trial to Investigate the Pharmacokinetics and Safety/Tolerability of CKD-386 in Healthy Male Volunteers

A Sequence-randomized, Open-label, 3-way Crossover, Single Oral Dose Clinical Trial to Investigate the Pharmacokinetic Characteristics and Safety/Tolerability According to Formulations of CKD-386 in Healthy Male Volunteers

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: Male
• Age: 19 Years – 45 Years
• Healthy volunteers: Accepted

Summary

a study to investigate the pharmacokinetic characteristics and safety/tolerability according to formulations of CKD-386 in healthy male volunteers

Detailed description

A sequence-randomized, open-label, 3-way crossover, single oral dose clinical trial to investigate the pharmacokinetic characteristics and safety/tolerability according to formulations of CKD-386 in healthy male volunteers

Conditions

• Hypertension
• Dyslipidemias

Interventions

Type	Name	Description
DRUG	CKD-386 formulation 1	A single oral dose of 1 tablet under fasting conditions for each period
DRUG	CKD-386 formulation 2	A single oral dose of 1 tablet under fasting conditions for each period
DRUG	D326, D337 and D013	A single oral dose of 3 tablets(D326, D337 and D013) under fasting conditions for each period

Timeline

• Start date: 2019-04-01
• Primary completion: 2019-05-01
• Completion: 2019-05-01
• First posted: 2019-04-19
• Last updated: 2019-04-19

Locations

1 site across 1 country: South Korea